Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Arcturus Therapeutics In...

    NASDAQ: ARCT · Real-Time Price · USD
    12.77
    0.86 (7.22%)
    At close: Jun 06, 2025, 3:59 PM
    12.81
    0.31%
    After-hours: Jun 06, 2025, 05:41 PM EDT
    7.22%
    Bid 12.6
    Market Cap 346.33M
    Revenue (ttm) 135.17M
    Net Income (ttm) -68.2M
    EPS (ttm) -2.52
    PE Ratio (ttm) -5.07
    Forward PE -4.11
    Analyst Buy
    Ask 13
    Volume 484,389
    Avg. Volume (20D) 449,069
    Open 12.11
    Previous Close 11.91
    Day's Range 12.05 - 12.93
    52-Week Range 8.04 - 42.42
    Beta 2.29

    About ARCT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ARCT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ARCT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 week ago
    +7.7%
    Arcturus Therapeutics shares are trading higher af... Unlock content with Pro Subscription
    3 weeks ago
    +2.33%
    Arcturus Therapeutics shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.
    news image

    3 days ago · zacks.com

    Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet

    The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

    news image

    1 week ago · businesswire.com

    Arcturus Therapeutics to Attend Upcoming Investor Conferences

    SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the developme...

    news image

    3 weeks ago · zacks.com

    Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade

    The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ear...

    news image

    3 weeks ago · seekingalpha.com

    Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

    Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Re...

    news image

    3 weeks ago · zacks.com

    Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates

    Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1 per share a year ago.

    news image

    1 month ago · zacks.com

    Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline

    Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · businesswire.com

    Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

    SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the developm...

    news image

    1 month ago · zacks.com

    Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

    The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

    news image

    3 months ago · seekingalpha.com

    Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

    Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne...

    news image

    3 months ago · zacks.com

    Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates

    Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago.

    Add to Watchlist